Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODE Chief Tillman Defends 510(k) Program At Minnesota Industry Meeting

This article was originally published in The Gray Sheet

Executive Summary

FDA's head of device evaluation is defending the agency's handling of 510(k) pre-market notification submissions in the face of criticism from two groups: those who charge the agency has allowed devices on the market without sufficient scientific evidence, and industry representatives who claim that FDA often demands too much from 510(k) applicants

You may also be interested in...



Device Center Discord: 510(k) Review Process Is Flash Point At CDRH

Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission

Device Center Discord: 510(k) Review Process Is Flash Point At CDRH

Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission

FDA Needs More Resources, Good Leadership, Daschle Tells Senate Panel

At a Jan. 8 confirmation hearing before the Senate Health, Education, Labor and Pensions Committee, HHS Secretary nominee Tom Daschle said that FDA needs more resources, better public policy and stronger leadership if it is to improve the device and drug approval processes and worker morale

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT026899

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel